Introduction
============

Cancer is one of the most common fatal diseases, which results from complex interactions between environmental and genetic factors \[[@B1]\]. More and more studies have focused on the role of gene polymorphism in the aetiology of cancers. Recently, there is growing evidence that single nucleotide polymorphism (SNP) plays an important role in carcinogenesis \[[@B2],[@B3]\]. DNA repair systems have been considered to maintain genomic integrity by counting threats posed by DNA lesions. Deficiency in the DNA repair pathways might make these lesions unrepaired or repaired incorrectly, eventually leading to genome instability or mutations which may contribute directly to cancer.

*RAD51* gene is located on chromosome 15q15.1 in humans \[[@B4]\]. The RAD51 protein encoding by *RAD51* gene is essential for the repair of DNA damage. Growing evidences show that RAD51 has an irreplaceable role in the maintenance of genomic stability and the repair of DNA double-strand breaks \[[@B5]\]. The *RAD51* genetic variations may contribute to the development of cancers \[[@B6]\]. A functional single nucleotide polymorphism, 135G/C (rs1801320), has been identified in the 5′ untranslated region of the *RAD51* gene \[[@B7]\] and has been reported to affect gene transcription activity \[[@B8]\].

Up to now, a variety of molecular epidemiological studies have been conducted to estimate the association between the *RAD51* 135G/C polymorphism and risk of various cancers \[[@B9]-[@B17]\], including squamous cell carcinoma of the head and neck \[[@B18]-[@B21]\], colorectal cancer \[[@B22]-[@B25]\], ovarian cancer \[[@B26]-[@B28]\] and acute leukaemia \[[@B29]-[@B37]\]. However, the results of previous studies on the association between *RAD51* 135G/C polymorphism and cancer risk have been inconclusive, partially because of the relatively small sample size of most studies. Therefore, we carried out this meta-analysis to evaluate the association between *RAD51* 135G/C polymorphism and risk of the four common types of cancers.

Methods
=======

Selection of eligible studies
-----------------------------

We conducted a comprehensive search in Pubmed, Cochrane library and Chinese Biomedical Literature Database (CBM), covering all articles published up to Oct 31, 2013, using the following terms: "*RAD51*" AND "polymorphism" AND "(squamous cell carcinoma of the head and neck) OR (colorectal cancer) OR (ovarian cancer) OR (acute leukaemia)". References of all identified studies and reviews were examined for additional articles.

Study assessment
----------------

Included studies in this meta-analysis met the following criteria: (a) a human case-control study on the association between *RAD51* 135G/C polymorphism and any of the four common cancers; (b) containing available genotype data in cases and controls for estimating an odds ratio (OR) and 95% confidence interval (CI); (c) genotype distributions of control population were consistent with Hardy-Weinberg equilibrium (HWE). The exclusion criteria were: (a) reviews, letters, editorial articles and case reports; (b) studies involving only a case population; (c) research not providing cancer information.

Data extraction
---------------

Two investigators (Cheng and Shi) extracted the data from all of the eligible publications according to the inclusion and exclusion criteria mentioned above. Primary extraction data were reviewed by Zhen, and any disagreement was resolved by discussion among the three authors. From each study, the following information was collected: first author's name, year of publication, study location, cancer type, sample size, source of control, the genotyping method, the number of genotype frequencies in cases and controls.

Statistical analysis
--------------------

For each case-control study, we first examined whether the genotype frequencies in controls were consistent with HWE. ORs and 95% CIs were calculated as a measure of the association between the *RAD51* 135G/C gene polymorphism and risk of the four cancers. The pooled ORs were performed for the homozygote comparison (G/G vs. C/C), heterozygote comparison (G/C vs. C/C), dominant (G/G + G/C vs. C/C) and recessive (G/G vs. G/C + C/C) genetic model comparison, and the significances of the summary ORs were determined by *Z* test, *P* \< 0.05 was considered as statistically significant. The chi-square-based *Q*-test was used to assess the statistical heterogeneity among studies, and it was considered significant if *P* \< 0.10 \[[@B38]\]. If the *P* value greater than 0.10, indicating the absence of heterogeneity, then a fixed-effects model (the Mantel-Haenszel method) was applied to calculate the summary ORs \[[@B39]\]. Otherwise, the random-effects model (the DerSimonian and Laird method) was used \[[@B40]\]. *I*^2^ was also calculated to test heterogeneity among included studies, with *I*^2^ \< 25%, 25-75%, and \>75% considered to represent low, moderate and high degree of heterogeneity, respectively \[[@B41]\]. Sensitivity analysis was performed to estimate the stability of the results, each study involved in this meta-analysis was deleted each time to reflect the influence of the individual data set to pooled ORs. Publication bias within the literature was assessed using Begg's test \[[@B42]\], an asymmetric funnel plot showed a potential publication bias. Egger's linear regression test (*P* \< 0.05 was considered significant publication bias) was also used to evaluate the symmetry of the funnel plot \[[@B43]\]. All of the analyses were carried out with RevMan 5.0.23 (Cochrane Library Software, Oxford, UK) and STATA11.0 (STATA Corporation, College Station, TX, USA).

Results
=======

Study characteristics
---------------------

A total of 133 related publications were identified, of which 19 studies were not accepted since they were not full articles (6 reviews, 7 meta-analysis, 4 comments, 2 case-reports). Fifty-nine articles were not about the above four cancers, 33 publications were excluded because they did not meet the inclusion criteria (11 not case-control studies, 6 not human studies, 7 not present the usable data, 7 not the gene loci, 2 not about polymorphism research). Finally, 22 studies including 6836 cases and 8507 controls were included in this meta-analysis (Figure [1](#F1){ref-type="fig"}).

![Flow diagram of study selection.](1746-1596-9-18-1){#F1}

The main characteristics of these 22 included studies are summarized in Table [1](#T1){ref-type="table"}. There were 14 studies from European countries, 3 studies from Asian countries, 3 studies from American countries, 1 study from Australia and 1 study from Africa. In addition, 9 articles were population-based and 13 articles were hospital-based. The number of publications on SCCHN, colorectal, ovarian cancer and acute leukaemia were 4, 4, 5, and 9, respectively. The diagnosis of most of the cases was based on pathology. Healthy subjects matched for age and sex were used as controls. Polymerase chain reaction (PCR) or restriction fragment length polymorphism(RFLP) were performed as genotyping methods. The genotype distributions and HWE examination results were shown in Table [2](#T2){ref-type="table"}.

###### 

Characteristics of 22 published studies included in this meta-analysis

  **First author**            **Year**   **Study location**   **Cancer type**   **Sample size**   **Source of controls**   **Genotyping methods**
  --------------------------- ---------- -------------------- ----------------- ----------------- ------------------------ ------------------------
  1\. Lu JC                   2006       USA                  SCCHN             716/719           HCC                      PCR-RFLP
  2\. Gil J                   2011       Poland               CC                133/100           HCC                      PCR-RFLP
  3\. Webb PM                 2005       Australia            OC                548/335           PCC                      PCR
  4\. Gresner P               2012       Poland               SCCHN             81/111            PCC                      PCR
  5\. Seedhouse C             2004       UK                   AL                267/186           PCC                      PCR
  6\. Jawad M                 2006       UK                   AL                267/186           PCC                      PCR
  7\. Krupa R                 2011       Poland               CC                100/100           HCC                      PCR
  8\. Sliwinski T             2010       Poland               SCCHN             288/353           HCC                      PCR-RFLP
  9\. Hamdy MS                2011       Egypt                AL                50/30             HCC                      PCR-RFLP
  10\. Liu L                  2011       China                AL                625/704           HCC                      PCR
  11\. Romanowicz-MakowskaH   2012       Poland               CC                320/320           HCC                      PCR
  12\. WerbouckJ              2008       Belgium              SCCHN             152/157           HCC                      PCR
  13\. Romanowicz-MakowskaH   2011       Poland               OC                120/120           HCC                      PCR
  14\. Bhatla D               2008       USA                  AL                452/646           PCC                      PCR
  15\. Voso MT                2007       Italy                AL                160/161           HCC                      PCR-RFLP
  16\. Mucha B                2012       Poland               CC                200/200           HCC                      PCR-RFLP
  17\. Zhang ZQ               2009       China                AL                166/458           HCC                      PCR-RFLP
  18\. Auranen A (UK)         2005       UK                   OC                729/847           PCC                      PCR
  18\. Auranen A (USA)        2005       USA                  OC                326/419           PCC                      PCR
  18\. Auranen A (Danish)     2005       Denmark              OC                278/699           PCC                      PCR
  21\. Yang L                 2011       China                AL                379/704           HCC                      PCR
  22\. Rollinson S            2006       UK                   AL                479/952           PCC                      PCR

SCCHN: squamous cell carcinoma of the head and neck; CC: colorectal cancer; OC: ovarian cancer; AL: acute leukaemia; HCC: hospital-based case-control; PCC: population-based case-control; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism.

###### 

Distribution of RAD51 genotype and allele among cancer patients and controls

  **First author**             **Year**   **Case**   **GC**   **CC**   **Control**   **GC**   **CC**   **Case**   **C**   **Control**   **C**   **HWE**
  ---------------------------- ---------- ---------- -------- -------- ------------- -------- -------- ---------- ------- ------------- ------- ---------
  1\. Lu JC                    2006       624        91       1        622           96       1        1339       93      1340          98      0.17
  2\. Gil J                    2011       100        29       4        73            27       0        229        37      173           27      0.19
  3\. Webb PM                  2005       457        85       4        971           145      10       999        93      2087          165     0.08
  4\. Gresner P                2012       67         13       1        71            14       2        147        15      156           18      0.22
  5\. Seedhouse C              2004       210        44       3        166           18       2        464        50      350           22      0.08
  6\. Jawad M                  2006       210        44       3        166           18       2        464        50      350           22      0.08
  7\. Krupa R                  2011       61         36       3        36            35       29       158        42      107           93      0.003
  8\. Sliwinski T              2010       138        145      5        258           64       32       421        155     580           128     0.28
  9\. Hamdy MS                 2011       39         9        2        26            3        1        87         13      55            5       0.06
  10\. Liu L                   2011       72         25       8        511           175      18       169        25      1197          211     0.52
  11\. Romanowicz- MakowskaH   2012       51         56       213      91            164      65       158        482     346           294     0.57
  12\. Werbouck J              2008       136        15       1        134           23       0        287        17      291           23      0.32
  13\. Romanowicz-MakowskaH    2011       13         15       92       33            69       18       41         199     135           105     0.07
  14\. Bhatla D                2008       374        73       5        555           85       6        821        83      1195          97      0.18
  15\. Voso MT                 2007       125        33       2        142           18       1        283        37      302           20      0.61
  16\. Mucha B                 2012       161        34       5        157           37       6        356        44      351           49      0.05
  17\. Zhang ZQ                2009       117        47       2        315           123      20       281        51      753           163     0.08
  18\. Auranen A (Danish)      2005       241        36       1        616           78       5        518        38      1310          88      0.15
  18\. Auranen A (UK)          2005       642        84       3        745           100      2        1368       90      1590          104     0.48
  18\. Auranen A (USA)         2005       270        52       4        357           61       1        592        60      775           63      0.34
  21\. Yang L                  2011       268        101      10       511           175      18       637        121     1197          211     0.52
  22\. Rollinson S             2006       431        34       1        817           115      4        896        36      1749          123     0.98

HWE: *P* value for Hardy-Weinberg equilibrium for *RAD51* 135G/C polymorphism among controls.

Quantitative synthesis
----------------------

The evaluation of association between *RAD*51 135G/C gene polymorphism and the risk of the four types of cancers was summarized in Table [3](#T3){ref-type="table"}. Overall, no significant association was found between *RAD*51 135G/C gene polymorphism and the risk of the four cancers (G/G vs. C/C: OR = 0.83, 95%CI = 0.43-1.59, *P* = 0.57; G/C vs. C/C: OR = 0.90, 95%CI = 0.39-2.08, *P* = 0.81; G/G + G/C vs. C/C: OR = 0.82, 95%CI = 0.39-1.73, *P* = 0.60; G/G vs. G/C + C/C: OR = 0.84, 95%CI = 0.69-1.02, *P* = 0.08). However, in the subgroup analysis by cancer type, there was a significant association between this polymorphism and SCCHN under homozygote comparison (G/G vs. C/C: OR = 2.46, 95%CI = 1.08-5.61; *P* = 0.03) (Figure [2](#F2){ref-type="fig"}). There was no significant association between this polymorphism and the risk of other three cancers under all comparisons. In the subgroup analyses by ethnicity or source of controls, no significant association was found in different genetic models.

###### 

Total and stratified analysis of the RAD51 135G/C polymorphism on risk of the four cancers

  **Variables**            **No.**^**a**^   **Case/Control**   **GG vs. CC**       **GC vs. CC**   **GG+GC vs. CC**   **GG vs. GC+CC**                                                                                       
  ------------------------ ---------------- ------------------ ------------------- --------------- ------------------ ------------------- --------- ------ ------------------- --------- ------ ------------------ --------- ------
  **Total cancer types**   22               6836/8507          0.83(0.43--1.59)    0.00^c^         0.57               0.90(0.39--2.08)    0.00^c^   0.81   0.82(0.39--1.73)    0.00^c^   0.60   0.84(0.69--1.02)   0.00^c^   0.08
  SCCHN                    4                1237/1340          2.46(1.08--5.61)    0.50            0.03               2.20(0.30--16.22)   0.02      0.44   2.50(0.76--8.28)    0.25      0.13   0.84(0.40--1.75)   0.00^c^   0.64
  CC                       4                753/720            0.92(0.08--10.55)   0.00^c^         0.95               0.65(0.05--8.08)    0.00^c^   0.74   0.79(0.06--10.16)   0.00^c^   0.85   1.12(0.53--2.35)   0.00^c^   0.77
  OC                       5                2001/2420          0.42(0.10--1.78)    0.0007          0.24               0.41(0.06--2.67)    0.00^c^   0.35   0.40(0.07--2.18)    0.00^c^   0.29   0.80(0.62--1.03)   0.07      0.09
  AL                       9                2845/4027          0.82(0.49--1.39)    0.26            0.47               1.00(0.59--2.08)    0.29      0.99   0.85(0.50--1.44)    0.25      0.60   0.82(0.63--1.07)   0.002     0.14
  **Source of controls**                                                                                                                                                                                                     
  HCC                      13               3409/4126          0.77(0.30--1.98)    0.00^c^         0.58               0.79(0.24--2.60)    0.00^c^   0.70   0.74(0.26--2.13)    0.00^c^   0.58   0.82(0.60--1.12)   0.00^c^   0.20
  PCC                      9                3427/4381          0.93(0.53--1.62)    0.87            0.79               1.14(0.64--2.02)    0.87      0.66   0.95(0.54--1.67)    0.88      0.87   0.88(0.71--1.09)   0.01      0.25
  **Ethnicity**                                                                                                                                                                                                              
  Asian                    3                1170/1866          0.92(0.27--3.19)    0.01            0.90               0.98(0.28--3.40)    0.01      0.97   0.94(0.27--3.26)    0.009     0.92   0.94(0.77--1.14)   0.64      0.52
  Caucasian                18               5616/6611          0.80(0.36--1.79)    0.00^c^         0.59               0.86(0.31--2.38)    0.00^c^   0.77   0.79(0.32--1.95)    0.00^c^   0.61   0.83(0.65--1.05)   0.00^c^   0.13
  African                  1                50/30              0.75(0.06--8.70)                    0.82               1.50(0.10--23.07)             0.77   0.83(0.07--9.54)              0.88   0.55(0.16--1.90)             0.34

^a^Number of studies.

^b^P value of Q-test for heterogeneity test.

^c^Fixed-effects model was used when P value for heterogeneity test \<0.10, otherwise, random-effects model was used.

SCCHN: squamous cell carcinoma of the head and neck; CC: colorectal cancer; OC: ovarian cancer; AL: acute leukaemia.
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Test of heterogeneity
---------------------

For the comprehensive analysis, the *I*^2^ showed a stable variation under all comparisons (G/G vs. C/C: *P* \< 0.00001, *I*^2^ = 81%; G/C vs. C/C: *P* \< 0.00001, *I*^2^ = 89%; G/G + G/C vs. C/C: *P* \< 0.00001, *I*^2^ = 88%; G/G vs. G/C + C/C: *P* \< 0.00001, *I*^2^ = 78%). In the subgroup analyses of SCHNN and acute leukaemia, the *I*^2^ showed a low or moderate variation under all comparisons. In the subgroup analyses of colorectal cancer and ovarian cancer, under most comparisons, the moderate heterogeneity was detected. For source of controls, there was no significant heterogeneity under all comparisons of population-based case-control (PCC), except for heterozygous and dominant model comparisons (G/C vs. C/C: *P* \< 0.00001, *I*^2^ = 93%; G/G + G/C vs. C/C: *P* \< 0.00001, *I*^2^ = 92%) in hospital-based case-control (HCC). *P* value for heterogeneity was not significant under all comparisons in the subgroup analyses of Asian population, but in Caucasian group, there were high degree heterogeneity under heterozygous and dominant model comparisons (G/C vs. C/C: *P* \< 0.00001, *I*^2^ = 90%; G/G + G/C vs. C/C: *P* \< 0.00001, *I*^2^ = 89%).

Sensitivity analysis
--------------------

Sensitivity analyses were performed to assess the stability of the results in this meta-analysis. Statistically similar data were obtained after sequentially excluding each study, indicating that our results were statistically reliable.

Publication bias
----------------

Begg's funnel plot and Egger's test were used to assess the publication bias of included studies. Publication bias was not observed in Begg's funnel plot. The shape of the funnel plots showed to be symmetrical (G/G vs. C/C) and the Egger's test did not show any evidence of publication bias (*P* = 0.248 for G/G vs. C/C) (Figure [3](#F3){ref-type="fig"}). These data indicate that there is no significant publication bias in this meta-analysis.

![**Begg's funnel plot for publication bias in selection of studies on*RAD51*135G/C polymorphism (GG vs. CC;*P*for bias = 0.248).**](1746-1596-9-18-3){#F3}

Discussion
==========

The RAD51 protein encoding by *RAD51* gene is essential for the repair of DNA damage. A number of original studies have reported the association between *RAD51* 135G/C polymorphism and the risk of cancer with inconclusive results, These inconsistent results are possibly because of a small effect of the polymorphism on cancers risk or the relatively low statistical power of the published studies. To better understanding of this association,a meta-analysis, which potentially investigates a large number of individuals and could estimate the effect of a genetic factor on the risk of cancers, was needed to provid a quantitative approach for combining the results of various studies with the same topic, and for estimating and explaining their diversity \[[@B44],[@B45]\]. We performed a meta-analysis including 6836 cases and 8507 controls from 22 case-control studies to evaluate the association between *RAD51* 135G/C polymorphism and risk of SCCHN, colorectal cancer, ovarian cancer and acute leukaemia.

The overall population analysis showed no significant association between *RAD51* 135G/C polymorphism and risk of SCCHN, colorectal cancer, ovarian cancer and acute leukaemia in any genetic model. However, in the subgroup analysis by cancer type, we found that the 135G/C polymorphism of the *RAD51* gene was associated with a significantly increased SCCHN risk. There was an aggregated OR of 2.46 (95% CI = 1.08-5.61) for increased SCCHN susceptibility under homozygote comparison. This indicates that the *RAD51* 135G/C polymorphism may contribute to pathogenesis of SCCHN. GG genotype has been reported to enhance *RAD51* gene transcription activity \[[@B8]\], individuals with GG genotype may be more likely to develop SCCHN than those with CC or GC genotype. No associations were found between this polymorphism and the risk of colorectal cancer, ovarian cancer and acute leukaemia, which was consistent with previous reports \[[@B22],[@B23],[@B27]-[@B29],[@B32],[@B36]\].

Heterogeneity is one of the important issues in performing a meta-analysis. In the present meta-analysis, heterogeneity was found in almost all comparisons. Using random-effect models and the stratified analyses by cancer type, sources of control and ethnicity, the heterogeneity was significantly decreased in most of the comparisons. The sensitivity analysis did not alter the results of our meta-analysis, indicating the results are stable. Meanwhile, the publication bias for the association between *RAD51* 135G/C polymorphism and the risk of the four types of cancers were not detected.

The present meta-analysis has some limitations. First, the control subjects were not uniformly defined. Selection bias and classification bias were possible because the included controls may have other different risks of developing cancers. Second, in the subgroup analyses, the sample sizes of Asian and African population were relatively small, not having enough statistical power to explore the real association. Third, cancer is a multi-factorial disease, our meta-analysis was based on unadjusted estimates.

In conclusion, the GG genotype of *RAD51* 135G/C was associated with a significantly increased risk of SCCHN. However, there was no significant association between this polymorphism and colorectal cancer, ovarian cancer or acute leukaemia susceptibility.
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